The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Open accessAbstract
Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Abnormal Centrosome Amplification in the Absence of p53
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., & Woude, G. F. V. (1996) · Science · doi:10.1126/science.271.5256.1744 · Cited by 797
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Rudensky, A. Y. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01018.x · Cited by 765
Mechanisms of Taxol resistance related to microtubules
Orr, G. A., Verdier-Pinard, P., McDaid, H., & Horwitz, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206934 · Cited by 727
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Taxol binds to polymerized tubulin in vitro
Parness, J., & Horwitz, S. (1981) · The Journal of Cell Biology · doi:10.1083/jcb.91.2.479 · Cited by 620
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., & Horwitz, S. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119642 · Cited by 601
Klauber, N., Parangi, S., Flynn, E. A., Hamel, E., & D’Amato, R. J. (1997) · PubMed · Cited by 524
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Taxol: an antimitotic agent with a new mechanism of action
Manfredi, J. J., & Horwitz, S. B. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90025-1 · Cited by 483
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P., & Kalinski, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 464
Phase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Biological consequences of tumor hypoxia
HOCKEL, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90211-8 · Cited by 382
Alexandre, J., Hu, Y., Lu, W., Pelicano, H., & Huang, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3914 · Cited by 380
TLR signaling by tumor and immune cells: a double-edged sword
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210904 · Cited by 377
Guidebook to the cytoskeletal and motor proteins
(1994) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(94)90276-3 · Cited by 371
Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N. R., Milas, L., & Wallace, S. (1998) · PubMed · Cited by 340
Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F. O., Ferrandina, G., et al. (2005) · PubMed · Cited by 323
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L., Rubin, S., Curtin, J., Barakat, R., & Phillips, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1485 · Cited by 313
Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F. O., Ferrandina, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.298.11.1 · Cited by 303
Mechetner, E. B., Kyshtoobayeva, A. S., Zonis, S., Kim, H. J., Stroup, R., Garcia, R., Parker, R. J., & Fruehauf, J. P. (1998) · PubMed · Cited by 291
The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol
Byrd-Leifer, C. A., Block, E. F., Takeda, K., Akira, S., & Ding, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200108)31:8<2448::aid-immu2448>3.0.co;2-n · Cited by 287
Update on taxane development: new analogs and new formulations
Tkaczuk, K., & Yared, J. (2012) · Drug Design, Development and Therapy · doi:10.2147/dddt.s28997 · Cited by 247
Duan, Z., Foster, R., Bell, D. A., Mahoney, J., Wolak, K., Vaidya, A., Hampel, C., Lee, H., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0861 · Cited by 247
Fennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L., & Spriggs, D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.187 · Cited by 242
Characterization of the Taxol Binding Site on the Microtubule
Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G. I., & Horwitz, S. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.35.20235 · Cited by 235
Pharmaceutical aspects of paclitaxel
Panchagnula, R. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00188-4 · Cited by 220
Markman, M., Markman, J., Webster, K., Zanotti, K., Kulp, B., Peterson, G., & Belinson, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.195 · Cited by 220
Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxane
Singer, J. W. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.033 · Cited by 213
Zhang, L., Dermawan, K., Jin, M., Liu, R., Zheng, H., Xu, L., Zhang, Y., Cai, Y., Chu, Y., & Xiong, S. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.013 · Cited by 209
The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens
Simon, R., & Norton, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0560 · Cited by 207
Microtubule nucleation: γ-tubulin and beyond
Wiese, C., & Zheng, Y. (2006) · Journal of Cell Science · doi:10.1242/jcs.03226 · Cited by 199
Francis, P. A., Rowinsky, E. K., Schneider, J., Hakes, T. B., Hoskins, W. J., & Markman, M. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2961 · Cited by 191
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley, M. O., Webb, N. L., Anthony, F. H., Devanesan, P. D., Witman, P. A., Hemamalini, S., Chander, M. C., Baker, S. D., He, L., Horwitz, S. B., et al. (2001) · PubMed · Cited by 180
Dammermann, A., Desai, A. B., & Oegema, K. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00530-x · Cited by 177
Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer
Lau, D. H., Xue, L., Young, L. J. T., Burke, P. A., & Cheung, A. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.31 · Cited by 172
Javeed, A., Ashraf, M., Riaz, A., Ghafoor, A., Afzal, S., & Mukhtar, M. M. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.08.009 · Cited by 172
Recent Advances in the Chemistry of Taxol
Kingston, D. G. I. (2000) · Journal of Natural Products · doi:10.1021/np000064n · Cited by 172
Taxol: The chemistry and structure-activity relationships of a novel anticancer agent
Kingston, D. G. I. (1994) · Trends in Biotechnology · doi:10.1016/0167-7799(94)90120-1 · Cited by 169
Determinants of Paclitaxel Penetration and Accumulation in Human Solid Tumor
Kuh, H.-J., Jang, S. H., Wientjes, M. G., Weaver, J. R., & Au, J. L.-S. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34976-6 · Cited by 167
Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Ferlini, C., Cicchillitti, L., Raspaglio, G., Bartollino, S., Cimitan, S., Bertucci, C., Mozzetti, S., Gallo, D., Persico, M., Fattorusso, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0540 · Cited by 165
Clinical Pharmacokinetics of Paclitaxel
Sonnichsen, D. S., & Relling, M. V. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427040-00002 · Cited by 163
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Pfannenstiel, L. W., Lam, S. S. K., Emens, L. A., Jaffee, E. M., & Armstrong, T. D. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.001 · Cited by 159
Zhang, C. C., Yang, J.-M., White, E., Murphy, M., Levine, A., & Hait, W. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201658 · Cited by 159
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 156
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · PubMed · Cited by 150
Paclitaxel: new uses for an old drug
Dong, Z., Zhang, D., Yang, R., & Wang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s56801 · Cited by 149
Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity
Kemp, R. A., & Ronchese, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6497 · Cited by 146
Markman, M., Brady, M. F., Spirtos, N. M., Hanjani, P., & Rubin, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2620 · Cited by 143
Ohtsu, T., Sasaki, Y., Tamura, T., et al. (1995) · PubMed · Cited by 143
The shape of things to come: Structural and synthetic studies of taxol and related compounds
Kingston, D. G. I. (2006) · Phytochemistry · doi:10.1016/j.phytochem.2006.11.009 · Cited by 132
Vicari, A. P., Luu, R., Zhang, N., Patel, S., Makinen, S. R., Hanson, D. C., Weeratna, R. D., & Krieg, A. Μ. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0586-2 · Cited by 130
Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity
Ganguly, A., Yang, H., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0552 · Cited by 130
Coleman, R. L., Brady, W. E., McMeekin, D. S., Rose, P. G., Soper, J. T., Lentz, S. S., Hoffman, J. S., & Shahin, M. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.036 · Cited by 122
Márkász, L., Stuber, G., Vanherberghen, B., Flaberg, E., Oláh, É., Carbone, E., Eksborg, S., Klein, E., Skribek, H., & Székely, L. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0358 · Cited by 110
Fialová, A., Partlová, S., Sojka, L., Hromádková, H., Brtnický, T., Fucikova, J. P., Kocián, P., Rob, L., Bartůňková, J., & Špíšek, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27759 · Cited by 108
Albers, A. E., Ferris, R. L., Kim, G. G., Chikamatsu, K., DeLeo, A. B., & Whiteside, T. L. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0670-9 · Cited by 105
Clinical trials and progress with paclitaxel in ovarian cancer
Kumar, S., Mahdi, Shah, Garg, Bryant, & Munkarah (2010) · International Journal of Women s Health · doi:10.2147/ijwh.s7012 · Cited by 103
Tumor targeting by conjugation of DHA to paclitaxel
Bradley, M. O., Swindell, C. S., Anthony, F. H., Witman, P. A., Devanesan, P. D., Webb, N. L., Baker, S. D., Wolff, A. C., & Donehower, R. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00321-2 · Cited by 101
Sherman‐Baust, C. A., Becker, K. G., Wood, W. H., Zhang, Y., & Morin, P. J. (2011) · Journal of Ovarian Research · doi:10.1186/1757-2215-4-21 · Cited by 94
Hadzic, T., Aykin‐Burns, N., Zhu, Y., Coleman, M. C., Leick, K. M., Jacobson, G., & Spitz, D. R. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.018 · Cited by 92
Yang, X., Iyer, A. K., Singh, A., Milane, L. S., Choy, E., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1602-1 · Cited by 91
Wu, X., Feng, Q., Wang, Y., Shi, J., Ge, H., & Di, W. J. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0749-9 · Cited by 84
Teneriello, M. G., Tseng, P. C., Crozier, M., Encarnacion, C. A., Hancock, K. C., Messing, M. J., Boehm, K. A., Williams, A., & Asmar, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9548 · Cited by 80
Wolff, A. C., Donehower, R. C., Carducci, M., Carducci, M. A., Brahmer, J. R., Zabelina, Y., Bradley, M. O., Anthony, F. H., Swindell, C. S., Witman, P. A., et al. (2003) · PubMed · Cited by 80
From taxol to taxol®: The changing identities and ownership of an anti-cancer drug
Walsh, V., & Goodman, J. (2002) · Medical Anthropology · doi:10.1080/01459740214074 · Cited by 79
Walsh, V., & Goodman, J. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00161-6 · Cited by 78
Th, W., Chan, Y.-H., Chen, C., Kung, W.-H., Lee, Y.-S., Wang, S., Chang, T.-C., & Wang, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209498 · Cited by 77
Weekly administration of paclitaxel: theoretical and clinical basis
Marchetti, P., Urien, S., Cappellini, G. A., Ronzino, G., & Ficorella, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00109-9 · Cited by 77
Pignata, S., Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., Vivo, R. D., Ferrandina, G., Gallo, C., et al. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.005 · Cited by 75
Arao, S., Suwa, H., Mandai, M., et al. (1994) · PubMed · Cited by 74
Matsuoka (1992) · International Journal of Oncology · doi:10.3892/ijo_00000153 · Cited by 73
Bhatt, R. S., Merchan, J. R., Parker, R. A., Wu, H., Zhang, L., Seery, V. J., Heymach, J. V., Atkins, M. B., McDermott, D. F., & Sukhatme, V. P. (2010) · Cancer · doi:10.1002/cncr.24902 · Cited by 72
Intraperitoneal therapy of ovarian cancer.
Markman, M. M. (1998) · PubMed · Cited by 72
Role of hypoxia in tumor angiogenesis?molecular and cellular angiogenic crosstalk
Acker, T., & Plate, K. H. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0763-8 · Cited by 70
Yakirevich, E., Sabo, E., Naroditsky, I., Sova, Y., Lavie, O., & Resnick, M. B. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.050 · Cited by 68
Johnatty, S. E., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M. H., Henderson, M. J., Russell, A. J., Hedditch, E. L., Emmanuel, C., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.107 · Cited by 65
Rizzo, J. D., Riley, C. M., Hoff, D. D. V., Kuhn, J. G., Phillips, J. L., & Brown, T. J. (1990) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(90)80023-i · Cited by 64
Taxanes: Old drugs, new oral formulations
Jibodh, R. A., Lagas, J. S., Nuijen, B., Beijnen, J. H., & Schellens, J. H. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.058 · Cited by 62
Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors
Jang, S. H., Wientjes, M. G., & Au, J. L. ‐. (2001) · Investigational New Drugs · doi:10.1023/a:1010662413174 · Cited by 61
Sabbatini, P. J., Sill, M. W., O’Malley, D. M., Adler, L. M., & Secord, A. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.049 · Cited by 60
Defeating drug resistance in cancer.
Gottesman, M. M., Ludwig, J. A., Xia, D., & Szakács, G. (2006) · PubMed · Cited by 60
Sevko, A., Kremer, V., Falk, C. S., Umansky, L., Shurin, M. R., Shurin, G. V., & Umansky, V. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.655343 · Cited by 58
Spriggs, D. R., Brady, M. F., Vaccarello, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3846 · Cited by 57
Fracasso, P. M., Picus, J., Wildi, J. D., Goodner, S. A., Creekmore, A. N., Gao, F., Govindan, R., Ellis, M. J., Tan, B. R., Linette, G. P., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0756-0 · Cited by 52
Sparreboom, A., Wolff, A. C., Verweij, J., Zabelina, Y., van Zomeren, D. M., McIntire, G. L., Swindell, C. S., Donehower, R. C., & Baker, S. D. (2003) · PubMed · Cited by 52
WANG, A.-C., Ma, Y.-B., WU, F.-X., Ma, Z., Liu, N., Gao, R., Gao, Y., & Sheng, X. (2013) · Oncology Letters · doi:10.3892/ol.2013.1759 · Cited by 50
Update on first-line treatment of advanced ovarian carcinoma
Ledermann, J. A., & Kemp (2013) · International Journal of Women s Health · doi:10.2147/ijwh.s30231 · Cited by 50
Guidelines for the administration of amifostine.
Lm, S. (1996) · PubMed · Cited by 45
Ando, M., Yonemori, K., Katsumata, N., Shimizu, C., Hirata, T., Yamamoto, H., Hashimoto, K., Yunokawa, M., Tamura, K., & Fujiwara, Y. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1726-5 · Cited by 41
Kubo, M., Morisaki, T., Matsumoto, K., Tasaki, A., Yamanaka, N., Nakashima, H., Kuroki, H., Nakamura, K., Nakamura, M., & Katano, M. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0617-6 · Cited by 39
van der Burg, M. E. L., Onstenk, W., Boere, I. A., Look, M. P., Ottevanger, P. B., de Gooyer, D., Kerkhofs, L. G. M., Valster, F. A. A., Ruit, J. B., van Reisen, A. G. P. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.015 · Cited by 38
Harnessing the immune system for the treatment of breast cancer
Jiang, X. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1300264 · Cited by 36
Liu, N., Zheng, Y., Zhu, Y., Xiong, S., & Chu, Y. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.11.021 · Cited by 35
O’Donnell, P. H., Gamazon, E. R., Zhang, W., Stark, A. L., Kistner‐Griffin, E., Huang, R. S., & Dolan, M. E. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283396c4e · Cited by 32
Dose-dense Paclitaxel in Advanced Ovarian Cancer
Kumar, A., Hoskins, P. J., & Tinker, A. V. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.10.001 · Cited by 31
Paclitaxel sensitivity correlates with P53 status and DNA fragmentation, but not G2/M accumulation
Rakovitch, E., Mellado, W., Hall, E. J., Pandita, T. K., Sawant, S. G., & Geard, C. R. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00109-1 · Cited by 31
Mita, M. M., Mita, A. C., Sarantopoulos, J., Takimoto, C. H. M., Rowinsky, E. K., Romero, O., Angiuli, P., Allievi, C., Eisenfeld, A. J., & Verschraegen, C. F. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0869-5 · Cited by 30
Harano, K., Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., & Sugiyama, T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt527 · Cited by 29
Zajchowski, D. A., Karlan, B. Y., & Shawver, L. K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0746 · Cited by 28
Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy
Sako, T., Burioka, N., Yasuda, K., Tomita, K., Miyata, M., Kurai, J., Chikumi, H., Watanabe, M., Suyama, H., Fukuoka, Y., et al. (2004) · Acta Oncologica · doi:10.1080/02841860310016226 · Cited by 23
Kikuchi, A., Sakamoto, H., & Yamamoto, T. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2005.15006.x · Cited by 22
Progress in systemic therapy for breast cancer: an overview and perspectives
Piccart, M. J., & Cardoso, F. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)00009-0 · Cited by 16
Huang, L., Zhang, Q., Ao, Q., Xing, H., Lu, Y., & Ma, D. (2007) · PubMed · Cited by 8
Safra, T., Shamai, S., Greenberg, J., Veizman, A., Shpigel, S., Matcejevsky, D., Pelles, S., Inbar, M., Levy, T., & Grisaru, D. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.06.013 · Cited by 6
Cited by
Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
Vangijzegem, T., Stanicki, D., & Laurent, S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1554647 · Cited by 548
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents
Hashem, S., Ali, T. A., Akhtar, S., Nisar, S., Sageena, G., Ali, S., Al-Mannai, S., Therachiyil, L., Mir, R., Elfaki, I., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113054 · Cited by 377
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Metadata
- Authors
- Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-21
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1574056173
- Cited by
- 362
- References
- 133
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.